National Institutes of Health orders Polarean’s lung imaging system

Published 25/09/2025, 12:18
National Institutes of Health orders Polarean’s lung imaging system

BETHESDA, Maryland - Medical imaging technology company Polarean Imaging plc (AIM:POLX) has received an order for its Xenon MRI System from the National Institutes of Health Clinical Center in Bethesda, Maryland, according to a company press release issued Thursday.

This marks the first system purchased directly from Polarean by the NIH, which operates the world’s largest hospital dedicated exclusively to clinical research.

The Xenon MRI System is designed for functional Magnetic Resonance Imaging of the lungs. The technology will enable the NIH Clinical Center to conduct high-performance polarization of Xenon for studies of innovative MRI techniques to better characterize lung disease.

The NIH Clinical Center, which opened in 1953, focuses on treating rare and severe diseases while conducting clinical research. The center serves as a facility for trials on rare diseases, experimental therapies, and medical research.

Dr. Christopher von Jako, CEO of Polarean, stated that the company will be working with Dr. Campbell-Washburn and her team at the NIH to conduct research on respiratory conditions.

Polarean Imaging is listed on London’s AIM market and specializes in commercial-stage medical imaging technology for lung function assessment using MRI.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.